IntroductionThe treatment of neuropathic pain with traditional and adjuvant analgesics is limited in efficacy and associated with severe adverse effects. Our group has previously shown that somatostatin, released from capsaicin-sensitive peptidergic sensory nerve terminals, mediates analgesic and anti-inflammatory effects at the peripheral and central levels via the somatostatin receptor subtype 4 (SST4). The therapeutic use of native somatostatin is limited by its numerous biological actions me
Comparative evaluation for small molecule somatostatin 4 receptor agonists: in silico, in vitro, and in vivo approaches
Erika Pintér
